Are you above the legal age to view this content in your province/state?

Home / Industry News / FSD Pharma amends deal with Solarvest BioEnergy to accelerate progress of CBD project

FSD Pharma amends deal with Solarvest BioEnergy to accelerate progress of CBD project

U.S., February 4, 2020 (proactive)- The project is determining if its algal expression system can create pharmaceutical-grade cannabinoids.

FSD Pharma amends deal with Solarvest BioEnergy to accelerate progress of CBD project

To enable Solarvest to accelerate the pace of the research, FSD Pharma has issued a further 225,371 of its shares

FSD Pharma Inc (CSE:HUGE) (NASDAQ:HUGE), the specialty biotech, revealed it had amended its deal with Solarvest Bioenergy Inc designed to accelerate progress on the latter’s CBD research project. 

As reported in May last year, Solarvest (CVE:SVS), based in Vancouver, British Columbia, holds a platform capable of producing health products from algae. 

The project, run by Solarvest, is determining if its algal expression system can create pharmaceutical-grade cannabinoids and has made progress towards this goal, said FSD.

Since this is a cost-intensive project, and, to enable Solarvest to accelerate the pace of the research, FSD Pharma has issued a further 225,371 of its shares to Solarvest, it also revealed in Tuesday’s statement.

In addition, Solarvest has appointed the current president of FSD Pharma’s BioSciences division – Dr. Edward J. Brennan, Jr –  to its board of directors.

“The parties have also mutually agreed that Solarvest would benefit from the additional oversight of Dr. Brennan, who brings with him over 25 years of experience in leadership roles at major pharmaceutical companies and clinical research organizations and has a proven track record in drug development,” said Ontario-headquartered FSD.

Significant potential benefits

There could be significant benefits to FSD Pharma.

If the CBD research project is successful, Solarvest is required to grant FSD an exclusive, worldwide license to develop and commercialize prescription drugs that can treat diseases affecting the central nervous system.

Solarvest will additionally provide FSD Pharma with a royalty fee on the sale or licensing of certain products derived from the project.

Solarvest owns numerous key patents. Its organic Omega-3 patent application has been filed and is pending in Europe, UK, USA, Canada, Japan, India, China, S. Korea, Hong Kong and Australia.

Being algae-based, the products are suitable for vegetarian and vegan diets.

Shares in FSD Pharma nudged up 2.66% to C$8.11 in early Toronto deals.

—Updates for share price–

Contact the author at giles@proactiveinvestors.com

Disclaimer

Investment Value Finders specializes in providing opinions and information on stocks to individuals who wish to receive them. Our reports are construed for information purposes solely and are distributed free of charge to individuals who wish to receive them.


Investment Value Finders does not promote, condone or advocate licit or illicit drug use. Investment Value Finders cannot be held responsible for materials or contests posted on its website pages, or pages to which we provide links, which promote, condone or advocate licit or illicit drug use or illegal activities.


DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE. We are not registered as a securities broker-dealer or an investment adviser. We are neither licensed nor qualified to provide investment advice.


Investment Value Finders occasionally receives direct compensation for hosting links (or other* advertisements) to third party content that may be subject to disclaimer pursuant to Section 17(b) of the Securities Act of 1933. For those instances where the link text contains company or stock-specific mention, we provide the following list of compensation received in order to ensure full disclosure and transparency.


Investment Value Finders is intended for those 21+ years of age only!

Check Also

Starbucks closing 130 licensed cafes in Russia

After a long time operating in Russia, Starbucks will exit the market, joining other occidental …